Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

ClinicalTrials.gov ID: NCT00807053

Public ClinicalTrials.gov record NCT00807053. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 9:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Randomized, Placebo-controlled, Parallel Group, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR)

Study identification

NCT ID
NCT00807053
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
480 participants

Conditions and interventions

Interventions

  • Ciclesonide HFA Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2007
Primary completion
May 31, 2007
Completion
Jun 30, 2007
Last update posted
Dec 4, 2016

2007

United States locations

U.S. sites
31
U.S. states
17
U.S. cities
31
Facility City State ZIP Site status
Altana/Nycomed Mission Viejo California 92691
Altana/Nycomed Orange California 92868
Altana/Nycomed San Diego California 92123
Altana/Nycomed Colorado Springs Colorado 80907
Altana/Nycomed Denver Colorado 80230
Altana/Nycomed Gainsville Georgia 30501
Altana/Nycomed Savannah Georgia 31406
Altana/Nycomed Stockbridge Georgia 30281
Altana/Nycomed Indianapolis Indiana 46208
Altana/Nycomed Overland Park Kansas 66210
Altana/Nycomed Bethesda Maryland 20814
Altana/Nycomed Minneapolis Minnesota 55402
Altana/Nycomed St Louis Missouri 63141
Altana/Nycomed Lincoln Nebraska 68505
Altana/Nycomed Papillion Nebraska 68046
Altana/Nycomed Skillman New Jersey 08558
Altana/Nycomed West Brick New Jersey 08724
Altana/Nycomed Raleigh North Carolina 27607
Altana/Nycomed Ashland Oregon 97520
Altana/Nycomed Medford Oregon 97504
Altana/Nycomed Portland Oregon 97213
Altana/Nycomed Blue Bell Pennsylvania 19422
Altana/Nycomed Pittsburgh Pennsylvania 15241
Altana/Nycomed Upland Pennsylvania 19013
Altana/Nycomed Charleston South Carolina 29414
Altana/Nycomed Austin Texas 78750
Altana/Nycomed New Braunfels Texas 78130
Altana/Nycomed San Antonio Texas 78229
Altana/Nycomed Draper Utah 84020
Altana/Nycomed Burke Virginia 22015
Altana/Nycomed Richmond Virginia 23226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00807053, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 4, 2016 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00807053 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →